![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ABBOTT LABORATORIES: CO-PROMOTION WITH BOEHRINGER INGELHEIM EXPIRES
ABBOTT LABORATORIES: CO-PROMOTION WITH BOEHRINGER INGELHEIM EXPIRES
August 1, 2005
Abbott Laboratories said in an SEC filing its co-promotion with Boehringer Ingelheim for three drugs has expired. A portion of the filing is below. Abbott and Boehringer Ingelheim Pharmaceuticals Inc. entered into a distribution and co-promotion agreement in 1999 in which Abbott was appointed Boehringer Ingelheim's distributor and co-promoter in the United States for three products manufactured by Boehringer Ingelheim: Mobic, Flomax and Micardis. Abbott's co-promotion for Mobic and Flomax has expired as provided in the agreement, and Abbott will co-promote Micardis through the end of March 2006. Abbott currently acts as distributor for these three products.
PharmaLive (http://www.medadnews.com/News/index.cfm?articleid=260925)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct